Sanofi SA (ADR) (NYSE:SNY) Expands Alliance With Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by Lacee Page January 14, 2014 0 Comment 1078 views

France based pharmaceutical firm Sanofi SA (ADR) (NYSE:SNY) has announced on the side lines of JP Morgan Healthcare Conference 2014 yesterday that its subsidiary Genzyme has expanded its existing strategic partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to cover time period till 2020. This agreement will cover the development and commercialization of drugs which are used to treat genetic disorders. Paris headquartered Sanofi SA (ADR) (NYSE:SNY) will be paying $700 million to Alnylam through its subsidiary Genzyme to acquire 12 percent ownership in Alnylam stock.

Sanofi SA (ADR) (NYSE:SNY) Gets Access To Alnylam Pipeline

In exchange, Sanofi SA (ADR) (NYSE:SNY) will be getting access to a host of development stage drugs of Alnylam which are going through clinical and pre clinical trials. The two companies will be co developing these identified drugs going forward and Alnylam will retain the rights to market these drugs in North America and Western Europe, where as the Paris based firm will have exclusive rights to market these drugs in rest of the world.

Win Win Situation

Commenting about the mutually beneficial deepening of their relationship, John Maraganore, Chief Executive Officer of Alnylam has been quoted as saying, “This new relationship with Genzyme is transformational for Alnylam. It is a game changer for both the advancement of RNAi therapeutics as a new class of genetic medicines to patients around the world, and for our commitment to build a leading, independent biopharmaceutical company that delivers value to our shareholders. In this new alliance, Alnylam benefits enormously from Genzyme’s proven global capabilities, enabling us to accelerate and expand market access for our ‘Alnylam 5×15′ products.”

It is worth noting that in 2012 the two firms Alnylam and Genzyme had entered into a exclusive partnership in order to co develop and commercialize a target drug of  Alnylam’s called “patisiran” which is currently progressed to Phase 3 trials.

About Lacee Page

Lacee Page is our White House and political campaign reporter. Lacee also covers justice and national law enforcement issues and congressional reporter focusing on the outputs of the legislative process: government spending, agency regulation and congressional oversight. Lacee received a national Edward R. Murrow for spot news award and the regional Associated Press award for best newscast. Lacee attended Riverview High School near Coshocton, and graduated from Ashland College in Ashland, Ohio with a Bachelor of Arts degree in Communications.

View all post by Lacee Page Visit author's website

Write Your Comment